Curriculum Vitae

**Deborah Gardner Nixon, MD**


**Practice Address:** Dermatology Specialists of Charlotte
8936 Blakeney Professional Drive
Charlotte, NC 28277
Deborah.nixon@dscmd.com

**Site Affiliation:**
2017-Present DJL Clinical Research, PLLC
431 N Wendover Rd
Charlotte, NC 28211


**Education:**

| | |
|---|---|
| 1995-1998 | Residency in Dermatology |
| 1997-1998 | Chief Administrative Resident<br>University of South Florida Medical Center<br>Tampa, Florida |
| 1993-1995 | Residency in Internal Medicine<br>Georgetown University Medical Center<br>Washington, DC |
| 1992-1993 | Internship in Internal Medicine<br>Vanderbilt University Medical Center<br>Nashville, Tennessee |
| 1988-1992 | Doctor of Medicine<br>University of North Carolina at Chapel Hill<br>School of Medicine<br>Chapel Hill, North Carolina |
| 1984-1988 | Bachelor of Science in Zoology<br>Duke University<br>Durham, North Carolina |

**Professional Experience:**

| | |
|---|---|
| 2006-Present | Dermatologist/Owner<br>Dermatology Specialists of Charlotte |
| 2000-2006 | Dermatologist<br>Carolina Dermatology |
| 1998-2000 | Dermatologist<br>The Dermatology Group, PA |

**Licensure/Certifications:**

- 1998-Present Dermatology Board Certified – State of North Carolina
- 1995-2005 Internal Medicine Board Certified– State of North Carolina

**Professional Memberships:**

| | |
|---|---|
| 1995-Present | Fellow of the American Academy of Dermatology |
| 2003-Present | Fellow of the American Society of Dermatologic Surgeons |
| 1998-Present | North Carolina Dermatology Association |
| 1999-Present | Mecklenburg County Medical Society |

**Clinical Research:**

**Sub-Investigator** – Abbvie: A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) –SELECT – PsA 2 (2017)

**Principal Investigator** – Cutanea Life Sciences, Inc: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 in Subjects 2 years of age or older with Cutaneous Common Warts (2017)

**Principal Investigator** – Vanda: A Randomized, Double-Blind, Placebo Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis. 2019

**Principal Investigator** – Chemocentryx: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa. 2019

**Principal Investigator** – Skintech: A Randomized, Double Blind, Phase 2, Comparative 16-Week Study of ACCUMAX SUBLINGUAL (Diindolylmethane, DIM + Vitamin A) and Quercetin vs Placebo in Participants with Moderate to Severe Acne Vulgaris. 2019

**Principal Investigator** – Eli Lilly: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata. BRAVE-AA2. 2019

**Principal Investigator** – Astrazeneca: A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis

**Principal Investigator** – Concert Pharmaceuticals: A Double-blind, Randomized, Placebo-controlled study to evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

**Principal Investigator** – Concert: A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

**Principal Investigator** – Concert: A Multicenter, Open-label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

**Principal Investigator** – AnaptysBio: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects with Moderate to Severe Alopecia Areata

**Principal Investigator** – Janssen: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Skin of Color who have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis

My signature verifies the information in this document is accurate and updated appropriately.

Signature

05 Jan 2023
Date